Summary of changes in the balances of the Company's contract assets and liabilities

The following table presents changes in the balances of the Company’s contract liabilities (in thousands):


	Beginning Balance						Impact of		Ending Balance
	January 1,						Exchange		December 31,
	2024		Additions		Deductions		Rates		2024
Contract liabilities:
Deferred revenue
Bayer collaboration deferred revenue	$	43,618	$	296	$	(3,393)	$	(561)	$	39,960
Novartis collaboration deferred revenue		50,008		3,000		(8,161)		(774)		44,073
Ionis collaboration deferred revenue		12,464		90		(8,881)		(86)		3,587
Genentech collaboration deferred revenue		29,104		—		(14,840)		(226)		14,038
Total deferred revenue	$	135,194	$	3,386	$	(35,275)	$	(1,647)	$	101,658


	Beginning Balance						Impact of		Ending Balance
	January 1,						Exchange		December 31,
	2023		Additions		Deductions		Rates		2023
Contract liabilities:
Deferred revenue
Bayer collaboration deferred revenue	$	—	$	45,000	$	(1,160)	$	(222)	$	43,618
Novartis collaboration deferred revenue		—		50,000		(1,909)		1,917		50,008
Ionis collaboration deferred revenue		21,489		960		(10,734)		749		12,464
Genentech collaboration deferred revenue		39,308		—		(11,969)		1,765		29,104
AstraZeneca collaboration deferred revenue		1,076		—		(1,204)		128		—
Total deferred revenue	$	61,873	$	95,960	$	(26,976)	$	4,337	$	135,194

Summary of allocation of transaction price to separate performance obligations

Based on the relative standalone selling prices, the allocation of the transaction price to the separate performance obligations was as follows (in thousands):


	Allocation of
Performance Obligations	Transaction Price
Two combined performance obligations related to the licenses and research and development services associated with radiopharmaceutical compounds directed to the first and second targets	$	14,976
Material right associated with limited substitution rights for either the first or second target		1,527
Two material rights associated with the option to progress radiopharmaceutical candidates directed to the first and second targets into further development		14,691
Two material rights associated with the option to progress a non-radiopharmaceutical compound directed to the first and second targets		8,703
Material right for the option to expand the collaboration to include a third target and the underlying additional option rights		7,603
	$	47,500

Significant agreements.

Summary of allocation of transaction price to separate performance obligations

Based on the relative standalone selling price, the initial allocation of the transaction price to the separate performance obligations was as follows (in thousands):


	Allocation of
Performance Obligations	Transaction Price
Combined licenses and research and discovery performance obligation	$	34,100
Four material rights associated with credits for IND Acceptance fees		3,900
	$	38,000

Significant agreements.